John Stewart, SVP Global Process Development at Fujifilm Biotechnologies, reflects on these lessons:“ The COVID-19 pandemic highlighted the critical need for resilient and adaptable manufacturing strategies in the biopharmaceutical industry. Key learnings include the importance of domestic onshoring, robust supply chains and the ability to rapidly scale up production in response to emerging health crises.”
These vulnerabilities, now heightened by geopolitical uncertainty, require a fundamental rethinking of how medicines are manufactured and distributed.
Contract development and manufacturing organisations( CDMOs) have emerged as crucial partners in building supply chain resilience, allowing biopharmaceutical companies to focus on drug discovery and development while outsourcing the complex challenge of large-scale manufacturing.
John explains:“ These vulnerabilities in biopharmaceutical manufacturing, now heightened by geopolitical uncertainty, require a new approach to ensure continuity of supply for medicines. CDMOs can play a critical role in ensuring supply chain resilience and Fujifilm Biotechnologies is setting a new standard.”
Building biopharma’ s TSMC John articulates an ambitious vision for Fujifilm’ s role in biopharmaceutical manufacturing, drawing a parallel to the semiconductor industry’ s most successful contract manufacturer.
230 January 2026